Key Questions for nAMD Treatment Success

Program Overview

Question: VA at Presentation

Improved Visual Outcomes in RCTs

VA Gains Greater in Patients With nAMD Who Have Lower Baseline VA

Vision is Better Preserved After 1 Year in Patients With Higher Baseline VA

Question: The Role of PCV Subtype

Effect of PCV Status on VA Gain in Treatment-Naive Patients With nAMD

Other Data on the Effect of PCV and PED Subtype on VA

Question: The Importance of the Loading Dose

Better Gains in VA at 12 Months With Loading Dose of Ranibizumab

Patients Who Received a Loading Dose Had a Greater Improvement in VA

Question: Intensive Therapy

The Effect of Intensive Anti-VEGF Therapy

Question: PRN or T&E

VA Gains at 12 Months With Different Treatment Regimens

Similar Gains in VA and Fewer Injections With T&E vs Monthly Dosing

T&E Has Greater Benefits Than PRN

Question: Injection Frequency

Pivotal Trials: Significant VA Gains With Monthly Anti-VEGF Therapy

Monthly Anti-VEGF Therapy vs PRN and T&E

PRN: Greater VA Gains With a Higher Injection Frequency

Barriers to Adequate Treatment

Question: Choice of Anti-VEGF Treatment

Ranibizumab vs Aflibercept

Question: Safety of Anti-VEGF Treatment

Safety of Ranibizumab

Summary

Abbreviations

Abbreviations (cont)